Company Overview

Red Light Holland Corp. is a Canada-based life sciences and wellness company operating in the psychedelics, functional mushrooms, and natural health products industries. The company focuses on the legal production, distribution, and branding of psilocybin-containing truffles in jurisdictions where permitted, as well as non-psychedelic mushroom and wellness products. Red Light Holland positions itself at the intersection of regulated psychedelics and consumer wellness, emphasizing compliance, intellectual property, and brand-driven market access.

The company’s primary revenue drivers have historically come from the sale of legal psilocybin truffles in the Netherlands, alongside functional mushroom and microdosing products sold under consumer brands. Founded in 2020, Red Light Holland evolved from a single-market psychedelic truffle business into a multi-asset platform through acquisitions, vertical integration, and expansion into research, distribution, and adjacent wellness categories. Its strategy emphasizes early participation in emerging regulated psychedelic markets while maintaining near-term revenue from legal operations.

Business Operations

Red Light Holland operates through several core business units, including Red Light Holland (Netherlands) BV, SR Wholesale, and iMicrodose, which together support cultivation, product development, branding, and distribution. The company generates revenue through direct-to-consumer and wholesale sales of legal psilocybin truffles in the Netherlands, as well as functional mushroom supplements and wellness products sold primarily in North America.

Internationally, operations include cultivation and packaging facilities in the Netherlands and distribution infrastructure in Canada. The company controls proprietary brands, formulations, and supply chains rather than relying solely on licensing. Red Light Holland has also maintained research-oriented assets through subsidiaries focused on psychedelics science and regulatory preparedness. If any segment-level revenue breakdown is required, data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Red Light Holland aims to be an early-stage leader in regulated psychedelics by combining compliant commercial sales with optionality in medical and research markets. Growth initiatives have included vertical integration, cost control through owned production, and the expansion of branded consumer wellness products that do not rely on regulatory reform to generate revenue.

Notable acquisitions include Halucenex Life Sciences Inc., a Nova Scotia–based psychedelics research and education company, and SR Wholesale, which strengthened the company’s North American distribution capabilities. The company has also invested in functional mushroom innovation and intellectual property related to microdosing and natural health formulations. Its portfolio reflects a diversified approach across recreationally legal, wellness, and research-oriented psychedelic assets.

Geographic Footprint

Red Light Holland’s operational footprint spans Europe and North America, with headquarters in Canada and core production activities in the Netherlands. The Netherlands remains the company’s most established market due to the legal status of psilocybin truffles, providing a foundation for international brand development and cash-generating operations.

In North America, the company maintains business operations, subsidiaries, and distribution networks in Canada, with exposure to the United States through wellness and non-psychedelic product channels where permitted. While the company monitors regulatory developments globally, its direct operational presence outside Europe and Canada remains limited based on publicly available disclosures.

Leadership & Governance

Red Light Holland was co-founded by entrepreneur and media personality Todd Shapiro, who has played a central role in shaping the company’s brand-forward and compliance-driven strategy. The leadership team combines experience in capital markets, consumer products, and emerging regulated industries, with a stated focus on transparency, responsible growth, and early-mover advantage in psychedelics.

Key executives include:

• Todd Shapiro – Chief Executive Officer
• Bruce Linton – Chairman
• Sarah Hashkes – Chief Operating Officer
• Jeff McDonald – Chief Financial Officer
• Russell Peters – Chief Creative Officer

Leadership has emphasized disciplined capital allocation, regulatory alignment, and leveraging well-known consumer brands to normalize and scale psychedelic-adjacent products within existing legal frameworks.